|BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured||smallcapvoice||01/30/23 2:45 PM|
|Strange stock, but I've loved having it the||Onree||01/20/23 11:19 AM|
|Yep, I'm still here. She's getting ready to||chenzo11||06/15/22 3:23 PM|
|Under $4 by end of month||Nickwvt||04/14/22 12:19 PM|
|BriaCell Therapeutics Price Target Announced at $25.00/Share by||crudeoil24||04/13/22 8:14 AM|
|BriaCell Reports Received FDA Fast Track Approval For||crudeoil24||04/13/22 8:10 AM|
|I'm still here....wait til you see what happens||chenzo11||04/09/22 12:12 AM|
|Closed above resistance of $10.50....We dance on Monday||chenzo11||11/19/21 4:41 PM|
|$BCTX BriaCell is an immuno-oncology focused biotechnology company||lucky__stock||11/05/21 10:44 AM|
|$BCTX announces the addition of Suzanne Ostrand-Rosenberg, Ph.D.||lucky__stock||11/05/21 10:22 AM|
|$BCTX has added Pioneering Immunologist and Cancer Immunotherapy||lucky__stock||11/05/21 9:58 AM|
|Easy Money for more $ZOM shares $BCTX thanks||EyalCap||10/03/21 1:45 PM|
|(Nasdaq: BCTX, BCTXW) (TSX-V: BCT) CEO highlights key||StockHighAlert-||09/23/21 11:49 AM|
|BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX-V:BCT) News||StockHighAlert-||08/23/21 10:58 AM|
|BCTX||Nebuchadnezzar||08/13/21 12:42 AM|
|MarketsandMarkets 4th Annual Next Gen Immuno-Oncology Virtual Congress-US||ThurstonHowell||06/29/21 2:00 PM|
|https://www.globenewswire.com/en/news-release/2021/05/11/2226965/0/en/BriaCell-t||ThurstonHowell||06/29/21 1:56 PM|
|https://www.globenewswire.com/news-release/2021/06/16/2248189/0/en/BriaCell-Ther||ThurstonHowell||06/16/21 3:04 PM|
|https://finance.yahoo.com/news/briacell-reports-12-0-months-111200861.html||ThurstonHowell||06/16/21 3:03 PM|
|Terrible timing though. Absolutely killed any momentum.||retireat40||06/03/21 8:31 PM|
|Yeah that wasn't bad news with private offering||HabibiFresh||06/03/21 11:47 AM|
|Hopefully the squeeze alone will take it over||jwakstock||06/03/21 11:23 AM|
|Yes, Nasdaq halted it again, Those MMS||timetomakemoney||06/03/21 10:56 AM|
|My hunch the halt is because there are||cbrad10480||06/03/21 10:52 AM|
|What the Hell, there was a market for||timetomakemoney||06/03/21 10:51 AM|
|PPS could go either way... My hunch||timetomakemoney||06/03/21 10:43 AM|
|I've never seen a halt for news and||cbrad10480||06/03/21 10:41 AM|
|We thinking buyout with this halt? Wouldn't halt||HabibiFresh||06/03/21 10:38 AM|
|Yeah real curious was about to happen||HabibiFresh||06/03/21 10:37 AM|
|100% resolution for eye-bulging tumors I love it||HabibiFresh||06/03/21 10:37 AM|
|Over an hour and BCTX is still halted.||timetomakemoney||06/03/21 10:35 AM|
|Yall seen a halt before big news before?||HabibiFresh||06/03/21 10:19 AM|
|Has to be more than that as it's||Penny chatter||06/03/21 10:11 AM|
|Offering news out...$5.26 with exercise at $6.17 it appears.||retireat40||06/03/21 9:46 AM|
|News Out! Public offering 5.2 million shares and warrants.||timetomakemoney||06/03/21 9:43 AM|
|Company: BriaCell Therapeutics Corp.||ANTADOG||06/03/21 9:17 AM|
|Look again||INFINITI||06/03/21 9:15 AM|
|Bid now 10 dollar, what i see, ANT||ANTADOG||06/03/21 9:14 AM|
|Yes.||Windsortrader519||06/03/21 8:56 AM|
|correction bid is now 8,50, fyi ANT||ANTADOG||06/03/21 8:44 AM|
|i hope this one gets attention from the||ANTADOG||06/03/21 8:43 AM|
|There is no bid or ask||INFINITI||06/03/21 8:41 AM|
|you mean why it stays 6,50 pm with||ANTADOG||06/03/21 8:19 AM|
|Did they halt this||INFINITI||06/03/21 8:11 AM|
|massive day here 146 million volume and counting||Nebuchadnezzar||06/02/21 6:42 PM|
|* * $BCTX Video Chart 06-02-2021 * *||ClayTrader||06/02/21 4:47 PM|
|Raised 27M - Market Cap 42M - with||aristotelisonassis||06/02/21 4:43 PM|
|Nope...shorts are killing this.||retireat40||06/02/21 4:02 PM|
|Great call...lol||retireat40||06/02/21 4:01 PM|
|something smells fish here. where is the big||aristotelisonassis||06/02/21 3:15 PM|
Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.
Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based vaccine technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.
In a preliminary Phase I clinical study in metastatic (i.e., Stage IV) breast cancer patients who had failed multiple treatments, Bria-IMT™ treatment significantly reduced the tumor size, without serious side effects. Importantly, the tumor regression was observed in other sites including the lung and even the brain -a difficult site. Impressively, the median lifespan of the patients was substantially longer than that of the comparable trials.
At our laboratory facility in Berkeley, CA, we are planning to expand our pipeline of oncology immunotherapy candidates using our proprietary technology platform.
Using the clinical data from the patients from the clinical studies, we are working to identify the molecular fingerprint of the patients for which the vaccine would be highly effective, and are planning to develop diagnostic testing products to identify this group. By directing the drug to the top-responders, we expect this approach to increase the likelihood of clinical trial success of Bria-IMT™ -to bring hope to thousands of cancer patients with few-to-no treatment options.
The company is currently recruiting its Phase I/IIa trial to further test Bria-IMT™ safety and activity in metastatic breast cancer patients. BriaCell maintains global rights for Bria-IMT™.
BriaCell is currently recruiting patients to evaluate the safety and activity of Bria-IMT™ in an additional Phase I/IIa study in 25-40 metastatic breast cancer patients who have failed at least one course of treatment.
For the details of the trial, please visit For the details of the trial, please visit https://www.clinicaltrials.gov/ct2/show/NCT03066947
FDA has approved the roll-over combination study of Bria-IMT™ with pembrolizumab (Keytruda; manufactured by Merck & Co., Inc.) or ipilimumab (Yervoy; manufactured by Bristol-Myers Squibb Company) for patients previously treated with BriaVax™ from the ongoing Phase I/IIa Clinical Trial in Advanced Breast Cancer. The study is available for patents on the SV-BR-1-GM Phase I/IIa study who develop progressive disease. These patients will be eligible to roll-over into combination therapy with Keytruda or Yervoy, depending on the type of breast cancer they have.
Manufactured by Merck & Co., Inc., KEYTRUDA® (pembrolizumab) is a prescription medicine that may treat certain cancers by working with the immune system. It has been approved for the treatment of a number of cancer indications excluding breast cancer.
For more information on pembrolizumab, please see:
Manufactured by Bristol-Myers Squibb Company, YERVOY® (ipilimumab) is a prescription medicine used in adults and children 12 years and older to treat melanoma (a kind of skin cancer) that has spread (metastatic) or cannot be removed by surgery (unresectable). It is a monoclonal antibody that works to activate the immune system and enabling them to recognize and destroy cancer cells.
For more informations on Ipilimumab, please see: